Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1351 to 1365 of 1371 results for patients and public

  1. Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]

    In development [GID-TA10977] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node positive early breast cancer

    In development [GID-DG10075] Expected publication date: 09 May 2024

    Diagnostics guidance
    In development

  3. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343

    In development [GID-TA11379] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Drug eluting stents for treating coronary heart disease: late stage assessment

    In development [GID-HTE10039] Expected publication date: TBC

    Health technology evaluations
    In development

  6. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  7. Palopegteriparatide for treating chronic hypoparathyroidism ID6380

    In development [GID-TA11454] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  9. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  11. Leadless cardiac pacemaker implantation for bradyarrhythmias

    Awaiting development [GID-IPG10340] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  12. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]

    In development [GID-TA11471] Expected publication date: 03 July 2024

    Technology appraisal guidance
    In development

  13. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    In development [GID-DG10054] Expected publication date: 10 July 2024

    Diagnostics guidance
    In development

  14. Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants

    In development [GID-IPG10351] Expected publication date: 13 November 2024

    Interventional procedures guidance
    In development

  15. Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]

    In development [GID-TA10980] Expected publication date: 17 July 2024

    Technology appraisal guidance
    In development